When your bone marrow turns into scar tissue
In short: Primary myelofibrosis is not just a blood disorder; it is a structural transformation of the body's internal factory. Instead of producing healthy cells, the bone marrow becomes increasingly fibrotic, forcing the body to create blood elsewhere and creating a complex cycle of cellular malfunction.
Primary myelofibrosis (PMF) is classified as a myeloproliferative neoplasm (MPN). It begins as a clonal hematopoietic stem cell malignancy where atypical megakaryocytes and myeloid cells proliferate uncontrollably. This abnormal growth triggers a cascade of events that fundamentally alters the bone marrow microenvironment, leading to progressive fibrosis—the thickening and scarring of the marrow tissue—and osteosclerosis.
The underlying mechanism is driven by constitutive signaling in the JAK/STAT pathway. Specifically, mutations in genes such as JAK2, MPL, or CALR lead to a state of constant activity. This results in the overproduction of cytokines, which act as chemical signals that stimulate the development of the fibrotic environment. As the marrow becomes less capable of housing healthy blood production, the body compensates through extramedullary hematopoiesis, where blood cell production occurs outside the bone marrow.
Clinically, this manifests as splenomegaly (enlarged spleen), cytopenias (low blood cell counts), and a significant risk of leukemic transformation into acute myeloid leukemia (AML). Because the disease is Philadelphia chromosome-negative, diagnosis relies on a combination of clinicopathologic features, genetic findings, and molecular studies. Recent updates in the WHO-5th classification and the 2022 International Consensus Classification (ICC) emphasize using next-generation sequencing to improve risk stratification and tailor specific treatment strategies for patients.
Understanding these molecular drivers is essential because they dictate both the progression of the disease and the patient's prognosis. By identifying specific mutations early, clinicians can better manage the transition from a chronic myeloproliferative state to more aggressive leukemic forms, aiming to improve long-term outcomes in a complex landscape of hematopoietic malignancy.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Primary Myelofibrosis - Overview (presentation, pathophysiology, investigation, treatment)
- Also: A Review of the Pathological and Molecular Diagnosis of Primary Myelofibrosis - PMC
To cite this card, link to https://intellectplus.co.uk/app/science-primary-myelofibrosis-overview-presentation-pathophysiology-.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Science · Latest · A–Z · All topics
